骨髓间充质干细胞干预实验性肺间质纤维化研究进展

Research Progress of Experimental Pulmonary Interstitial Fibrosis Intervened by Bone Marrow Mesenchymal Stem Cells

肺间质纤维化是一类进展迅速,预后差,且严重危害人类健康的疾病。由于(Bone marrow mesenchymal stem cells,BMSC)具有低免疫原性,多组织分化能力及免疫抑制功能,且来源广泛、培养中具有较好的稳定性,故在肺纤维化的治疗中具有较好的应用价值。西药诱导BMSC治疗肺纤维化疗效明显高于单独BMSC治疗,中药诱导BMSC治疗肺纤维化较少,且中药副作用相对于西药较少,故以中药诱导骨髓间充质干细胞治疗肺纤维化是一值得探索的方法。BMSC治疗肺纤维化的可能机制:代替坏死或消亡的细胞;减轻炎症反应及胶原沉积;抑制氧化应激反应。

Pulmonary interstitial fibrosis（ PIF） is a kind of disease severely affects people’s health,which is of rapid progress and bad prognosis. Since bone marrow mesenchymal stem cell（ BMSC） is of low immunogenicity,multiple histological differentiation,immunesuppression function,wide source and good stability in cultivation,it has good application value in the treatment of PIF.BMSC induced by western medicine in the treatment of PIF is remarkably more effective than single BMSC. BMSC induced by Chinese medicine is relatively few and the side effects of Chinese medicine are lower than those of western medicine. Therefore,BMSC induced by Chinese medicine for the treatment of PIF is a new exploratory method. The possible mechanisms in BMSC treating PIF include： replacing the dead cells,reducing the inflammatory reaction and collagen deposition,inhibiting the oxidative stress reaction.